Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2Gastrointestinal 1

Conditions

Neuroendocrine Tumors 394Carcinoid Tumor 49Gastro-enteropancreatic neuroendocrine tumor 42Neoplasms 36Carcinoma, Neuroendocrine 36Adenoma, Islet Cell 27Neoplasm Metastasis 23Pancreatic Neoplasms 22Colorectal Neoplasms 21Pheochromocytoma 20Paraganglioma 19Sarcoma 15Gastrointestinal Neoplasms 15Carcinoma 14Breast Neoplasms 14Stomach Neoplasms 13Prostatic Neoplasms 13Neuroblastoma 13Lung Neoplasms 13Carcinoma, Hepatocellular 13Thyroid Neoplasms 12Small Cell Lung Carcinoma 12Carcinoma, Renal Cell 11Cholangiocarcinoma 10Neuroectodermal Tumors, Primitive 9Carcinoma, Non-Small-Cell Lung 9Somatostatinoma 8Serotonin Syndrome 8Digestive System Neoplasms 8Brain Neoplasms 8

Interventions

lanreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Flushing × NET × Clear all
NCT00774930 2022-10-14

ELECT

Ipsen

Phase 3 Completed
115 enrolled 17 charts
EndocrineNET

Carcinoid Tumor, Diarrhea, Flushing, Neuroendocrine Tumors, Serotonin Syndrome

NCT01886287 2015-01-12

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
2 enrolled 4 charts
EndocrineNET

Diarrhea, Flushing, Neoplasm Metastasis, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡